{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T21:02:14Z","timestamp":1785013334205,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T00:00:00Z","timestamp":1510185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1038\/bjc.2017.279","type":"journal-article","created":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T23:47:38Z","timestamp":1510271258000},"page":"1777-1786","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer"],"prefix":"10.1038","volume":"117","author":[{"given":"Jordi","family":"Codony-Servat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Cuatrecasas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Asensio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Montironi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mart\u00ednez-Card\u00fas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Mar\u00edn-Aguilera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Horndler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Mart\u00ednez-Balibrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Rubini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Jares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Reig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e1n","family":"Victoria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Gaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mart\u00edn-Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Escudero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Fern\u00e1ndez-Martos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Feliu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Carlos","family":"M\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"M\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Gallego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonieta","family":"Salud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Rojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Castells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleix","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Rosell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xabier","family":"Garc\u00eda-Alb\u00e9niz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Camps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Maurel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,9]]},"reference":[{"key":"BFbjc2017279_CR1","doi-asserted-by":"publisher","first-page":"6412","DOI":"10.1158\/0008-5472.CAN-10-0052","volume":"70","author":"T Aleksic","year":"2010","unstructured":"Aleksic T, Chitnis MM, Perestenko OV, Gao S, Thomas PH, Turner GD, Protheroe AS, Howarth M, Macaulay VM (2010) Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells. Cancer Res 70: 6412\u20136419.","journal-title":"Cancer Res"},{"key":"BFbjc2017279_CR2","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1016\/j.ejca.2014.04.019","volume":"50","author":"V Alonso-Espinaco","year":"2014","unstructured":"Alonso-Espinaco V, Cuatrecasas M, Alonso V, Escudero P, Marmol M, Horndler C, Ortego J, Gallego R, Codony-Servat J, Garc\u00eda-Alb\u00e9niz X, Jares P, Castells A, Lozano JJ, Rosell R, Maurel J (2014) RAC1b overexpression correlates with poor prognosis in KRAS\/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX\/XELOX chemotherapy. Eur J Cancer 50: 1973\u20131981.","journal-title":"Eur J Cancer"},{"key":"BFbjc2017279_CR3","doi-asserted-by":"publisher","first-page":"iv204","DOI":"10.1093\/annonc\/mdu333.101","volume":"25","author":"V Alonso-Orduna","year":"2014","unstructured":"Alonso-Orduna V, Marmol M, Escudero P, Salud A, Safont MJ, M\u00e9ndez JC, Garc\u00eda-Gir\u00f3n C, Mart\u00edn M, Fernandez-Martos C, Garc\u00eda-Alb\u00e9niz X, Feliu J, Maurel J (2014) 599PA validation of current prognostic scores in metastatic colorectal cancer (mCRC) and a new prognostic score (a GEMCAD Study). Ann Oncol 25: iv204\u2013iv204.","journal-title":"Ann Oncol"},{"issue":"Suppl 6","key":"BFbjc2017279_CR4","first-page":"vi149","volume":"27","author":"V Alonso","year":"2016","unstructured":"Alonso V, Emperador PE, Urena MM, Gallego J, Rodriguez JR, Fern\u00e1ndez J, Salud A, Falc\u00f3 E, Manzano H, Zanui M, Gil M, Sarmiento UB, Martos CF, Calderero V, Ferrer AI, Cuatrecasas M, Rojo F, Feliu J, Maurel J, Garc\u00eda-Alb\u00e9niz X (2016) Prospective evaluation of BRAF, PI3K and PTEN as predictive and prognostic biomarkers in first-line advanced KRAS wild-type colorectal cancer treated with FOLFOX or FOLFIRI plus bi-weekly cetuximab. GEMCAD 10-02. Ann Oncol 27 (Suppl 6): vi149\u2013vi206.","journal-title":"Ann Oncol"},{"key":"BFbjc2017279_CR5","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1158\/1078-0432.CCR-16-0140","volume":"23","author":"D Barras","year":"2017","unstructured":"Barras D, Missiaglia E, Wirapati P, Sieber OM, Jorissen RN, Love C, Molloy PL, Jones IT, McLaughlin S, Gibbs P, Guinney J, Simon IM, Roth AD, Bosman FT, Tejpar S, Delorenzi M (2017) BRAF V600E mutant colorectal cancer subtypes based on gene expression. Clin Cancer Res 23: 104\u2013115.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2017279_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1006\/excr.1999.4667","volume":"253","author":"R Baserga","year":"1999","unstructured":"Baserga R (1999) The IGF-I receptor in cancer research. Exp Cell Res 253: 1\u20136.","journal-title":"Exp Cell Res"},{"key":"BFbjc2017279_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2217\/14796694.5.1.43","volume":"5","author":"R Baserga","year":"2009","unstructured":"Baserga R (2009) Customizing the targeting of IGF-1 receptor. Futur Oncol 5: 43\u201350.","journal-title":"Futur Oncol"},{"key":"BFbjc2017279_CR8","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/S0140-6736(13)61649-9","volume":"383","author":"H Brenner","year":"2014","unstructured":"Brenner H, Kloor M, Pox CP (2014) Colorectal cancer. Lancet 383: 1490\u20131502.","journal-title":"Lancet"},{"key":"BFbjc2017279_CR9","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1093\/annonc\/mdt057","volume":"24","author":"AL Cohn","year":"2013","unstructured":"Cohn AL, Tabernero J, Maurel J, Nowara E, Sastre J, Chuah BYS, Kopp M V, Sakaeva DD, Mitchell EP, Dubey S, Suzuki S, Hei Y-J, Galimi F, McCaffery I, Pan Y, Loberg R, Cottrell S, Choo S-P (2013) A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer. Ann Oncol Off J Eur Soc Med Oncol 24: 1777\u20131785.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"BFbjc2017279_CR10","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.bbrc.2010.12.038","volume":"404","author":"H Deng","year":"2011","unstructured":"Deng H, Lin Y, Badin M, Vasilcanu D, Str\u00f6mberg T, Jernberg-Wiklund H, Sehat B, Larsson O (2011) Over-accumulation of nuclear IGF-1 receptor in tumor cells requires elevated expression of the receptor and the SUMO-conjugating enzyme Ubc9. Biochem Biophys Res Commun 404: 667\u2013671.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFbjc2017279_CR11","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/bjc.2014.346","volume":"111","author":"J Feliu","year":"2014","unstructured":"Feliu J, Salud A, Safont MJ, Garc\u00eda-Gir\u00f3n C, Aparicio J, Vera R, Serra O, Casado E, Jorge M, Escudero P, Bosch C, Bohn U, P\u00e9rez-Carri\u00f3n R, Carmona A, Mart\u00ednez-Mar\u00edn V, Maurel J (2014) First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study. Br J Cancer 111: 241\u2013248.","journal-title":"Br J Cancer"},{"key":"BFbjc2017279_CR12","doi-asserted-by":"publisher","first-page":"5436","DOI":"10.1158\/1078-0432.CCR-10-2054","volume":"16","author":"SA Flanigan","year":"2010","unstructured":"Flanigan SA, Pitts TM, Eckhardt SG, Tentler JJ, Tan AC, Thorburn A, Leong S (2010) The insulin-like growth factor I receptor\/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models. Clin Cancer Res 16: 5436\u20135446.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2017279_CR13","first-page":"5278","volume":"60","author":"L Girnita","year":"2000","unstructured":"Girnita L, Girnita A, Brodin B, Xie Y, Nilsson G, Dricu A, Lundeberg J, Wejde J, Bartolazzi A, Wiman KG, Larsson O (2000) Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact. Cancer Res 60: 5278\u20135283.","journal-title":"Cancer Res"},{"key":"BFbjc2017279_CR14","doi-asserted-by":"publisher","first-page":"5048","DOI":"10.1158\/1078-0432.CCR-10-3131","volume":"17","author":"M Ii","year":"2011","unstructured":"Ii M, Li H, Adachi Y, Yamamoto H, Ohashi H, Taniguchi H, Arimura Y, Carbone DP, Imai K, Shinomura Y (2011) The efficacy of IGF-I receptor monoclonal antibody against human gastrointestinal carcinomas is independent of k-ras mutation status. Clin Cancer Res 17: 5048\u20135059.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2017279_CR15","doi-asserted-by":"publisher","first-page":"30643","DOI":"10.1074\/jbc.270.51.30643","volume":"270","author":"CL Johnston","year":"1995","unstructured":"Johnston CL, Cox HC, Gomm JJ, Coombes RC (1995) Fibroblast growth factor receptors (FGFRs) localize in different cellular compartments. A splice variant of FGFR-3 localizes to the nucleus. J Biol Chem 270: 30643\u201330650.","journal-title":"J Biol Chem"},{"key":"BFbjc2017279_CR16","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1093\/carcin\/bgr222","volume":"32","author":"E Kendziorra","year":"2011","unstructured":"Kendziorra E, Ahlborn K, Spitzner M, Rave-Frank M, Emons G, Gaedcke J, Kramer F, Wolff HA, Becker H, Beissbarth T, Ebner R, Ghadimi BM, Pukrop T, Ried T, Grade M (2011) Silencing of the Wnt transcription factor TCF4 sensitizes colorectal cancer cells to (chemo-) radiotherapy. Carcinogenesis 32: 1824\u20131831.","journal-title":"Carcinogenesis"},{"key":"BFbjc2017279_CR17","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/onc.2009.234","volume":"28","author":"C Li","year":"2009","unstructured":"Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL (2009) Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 28: 3801\u20133813.","journal-title":"Oncogene"},{"key":"BFbjc2017279_CR18","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/ncb0901-802","volume":"3","author":"SY Lin","year":"2001","unstructured":"Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, Bourguignon L, Hung MC (2001) Nuclear localisation of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 3: 802\u2013808.","journal-title":"Nat Cell Biol"},{"issue":"Suppl 6","key":"BFbjc2017279_CR19","first-page":"vi149","volume":"27","author":"J Maurel","year":"2016","unstructured":"Maurel J, Martos CF, Richard MM, Alonso V, M\u00e9ndez CM, Salud A, Pericay C, Aparicio J, Gallego J, Carmona A, Casado E, Manzano H, Horndler C, Rubini M, Cuatrecasas M, Garc\u00eda-Alb\u00e9niz X, Feliu J (2016) PULSE, a phase 2 study of mFOLFOX6-panitumumab (P) with biomarker stratification as first-line chemotherapy (CT), in patients (pts) with KRAS (exon 2) metastatic colorectal cancer (mCRC). A GEMCAD 09-03 study. Ann Oncol 27 (Suppl 6): vi149\u2013vi206.","journal-title":"Ann Oncol"},{"key":"BFbjc2017279_CR20","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1111\/tra.12090","volume":"14","author":"M Niu","year":"2013","unstructured":"Niu M, Wu S, Mao L, Yang Y (2013) CRM1 is a cellular target of curcumin: new insights for the myriad of biological effects of an ancient spice. Traffic 14: 1042\u20131052.","journal-title":"Traffic"},{"key":"BFbjc2017279_CR21","first-page":"1","volume":"34","author":"S Packham","year":"2014","unstructured":"Packham S, Warsito D, Lin Y, Sadi S, Karlsson R, Sehat B, Larsson O (2014) Nuclear translocation of IGF-1R via p150(Glued) and an importin-\u03b2\/RanBP2-dependent pathway in cancer cells. Oncogene 34: 1\u201312.","journal-title":"Oncogene"},{"key":"BFbjc2017279_CR22","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/nrc2536","volume":"8","author":"M Pollak","year":"2008","unstructured":"Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8: 915\u2013928.","journal-title":"Nat Rev Cancer"},{"key":"BFbjc2017279_CR23","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1200\/JCO.2011.39.5814","volume":"30","author":"V Popovici","year":"2012","unstructured":"Popovici V, Budinska E, Tejpar S, Weinrich S, Estrella H, Hodgson G, Van Cutsem E, Xie T, Bosman FT, Roth AD, Delorenzi M (2012) Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. J Clin Oncol 30: 1288\u20131295.","journal-title":"J Clin Oncol"},{"key":"BFbjc2017279_CR24","doi-asserted-by":"publisher","first-page":"11482","DOI":"10.1038\/ncomms11482","volume":"7","author":"T Ritterhoff","year":"2016","unstructured":"Ritterhoff T, Das H, Hofhaus G, Schr\u00f6der RR, Flotho A, Melchior F (2016) The RanBP2\/RanGAP1*SUMO1\/Ubc9 SUMO E3 ligase is a disassembly machine for Crm1-dependent nuclear export complexes. Nat Commun 7: 11482.","journal-title":"Nat Commun"},{"key":"BFbjc2017279_CR25","doi-asserted-by":"publisher","first-page":"e14157","DOI":"10.1371\/journal.pone.0014157","volume":"5","author":"B Salani","year":"2010","unstructured":"Salani B, Passalacqua M, Maffioli S, Briatore L, Hamoudane M, Contini P, Cordera R, Maggi D (2010) IGF-IR internalizes with caveolin-1 and PTRF\/Cavin in Hacat cells. PLoS One 5: e14157.","journal-title":"PLoS One"},{"key":"BFbjc2017279_CR26","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","volume":"26","author":"LB Saltz","year":"2008","unstructured":"Saltz LB, Clarke S, D\u00edaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang T-S, Rivera F, Couture F, Sirz\u00e9n F, Cassidy J (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26: 2013\u20132019.","journal-title":"J Clin Oncol"},{"key":"BFbjc2017279_CR27","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/jcb.22558","volume":"110","author":"M Saydmohammed","year":"2010","unstructured":"Saydmohammed M, Joseph D, Syed V (2010) Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells. J Cell Biochem 110: 447\u2013456.","journal-title":"J Cell Biochem"},{"key":"BFbjc2017279_CR28","doi-asserted-by":"publisher","first-page":"e340","DOI":"10.1371\/journal.pone.0000340","volume":"2","author":"B Sehat","year":"2007","unstructured":"Sehat B, Andersson S, Vasilcanu R, Girnita L, Larsson O (2007) Role of ubiquitination in IGF-1 receptor signaling and degradation. PLoS One 2: e340.","journal-title":"PLoS One"},{"key":"BFbjc2017279_CR29","doi-asserted-by":"publisher","first-page":"ra10","DOI":"10.1126\/scisignal.2000628","volume":"3","author":"B Sehat","year":"2010","unstructured":"Sehat B, Tofigh A, Lin Y, Trocm\u00e9 E, Liljedahl U, Lagergren J, Larsson O (2010) SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor. Sci Signal 3: ra10.","journal-title":"Sci Signal"},{"key":"BFbjc2017279_CR30","doi-asserted-by":"publisher","first-page":"23216","DOI":"10.1074\/jbc.M111.335927","volume":"287","author":"M Sundvall","year":"2012","unstructured":"Sundvall M, Korhonen A, Vaparanta K, Anckar J, Halkilahti K, Salah Z, Aqeilan RI, Palvimo JJ, Sistonen L, Elenius K (2012) Protein inhibitor of activated STAT3 (PIAS3) protein promotes SUMOylation and nuclear sequestration of the intracellular domain of ErbB4 protein. J Biol Chem 287: 23216\u201323226.","journal-title":"J Biol Chem"},{"key":"BFbjc2017279_CR31","doi-asserted-by":"publisher","first-page":"4240","DOI":"10.1158\/1078-0432.CCR-13-2752","volume":"20","author":"E Van Cutsem","year":"2014","unstructured":"Van Cutsem E, Eng C, Nowara E, Swieboda-Sadlej A, Tebbutt NC, Mitchell E, Davidenko I, Stephenson J, Elez E, Prenen H, Deng H, Tang R, McCaffery I, Oliner KS, Chen L, Gansert J, Loh E, Smethurst D, Tabernero J (2014) Randomized phase Ib\/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer. Clin Cancer Res 20: 4240\u20134250.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2017279_CR32","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","volume":"29","author":"E Van Cutsem","year":"2011","unstructured":"Van Cutsem E, K\u00f6hne C-H, L\u00e1ng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29: 2011\u20132019.","journal-title":"J Clin Oncol"},{"key":"BFbjc2017279_CR33","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cell.2016.02.059","volume":"165","author":"L Vecchione","year":"2016","unstructured":"Vecchione L, Gambino V, Raaijmakers J, Schlicker A, Fumagalli A, Russo M, Villanueva A, Beerling E, Bartolini A, Mollevi DG, El-Murr N, Chiron M, Calvet L, Nicolazzi C, Combeau C, Henry C, Simon IM, Tian S, in \u2018t Veld S, D\u2019ario G, Mainardi S, Beijersbergen RL, Lieftink C, Linn S, Rumpf-Kienzl C, Delorenzi M, Wessels L, Salazar R, Di Nicolantonio F, Bardelli A, van Rheenen J, Medema RH, Tejpar S, Bernards R (2016) A vulnerability of a subset of colon cancers with potential clinical utility. Cell 165: 317\u2013330.","journal-title":"Cell"},{"key":"BFbjc2017279_CR34","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ccr.2004.07.012","volume":"6","author":"S-C Wang","year":"2004","unstructured":"Wang S-C, Lien H-C, Xia W, Chen I-F, Lo H-W, Wang Z, Ali-Seyed M, Lee D-F, Bartholomeusz G, Ou-Yang F, Giri DK, Hung M-C (2004) Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell 6: 251\u2013261.","journal-title":"Cancer Cell"},{"key":"BFbjc2017279_CR35","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/embor.2011.251","volume":"13","author":"D Warsito","year":"2012","unstructured":"Warsito D, Sj\u00f6str\u00f6m S, Andersson S, Larsson O, Sehat B (2012) Nuclear IGF1R is a transcriptional co-activator of LEF1\/TCF. EMBO Rep 13: 244\u2013250.","journal-title":"EMBO Rep"},{"key":"BFbjc2017279_CR36","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0065-230X(08)60354-1","volume":"68","author":"H Werner","year":"1996","unstructured":"Werner H, LeRoith D (1996) The role of the insulin-like growth factor system in human cancer. Adv Cancer Res 68: 183\u2013223.","journal-title":"Adv Cancer Res"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2017279.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2017279","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bjc.2017.279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2017279.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T14:08:06Z","timestamp":1719583686000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2017279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,9]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["BFbjc2017279"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2017.279","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,9]]},"assertion":[{"value":"15 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}